1. Home
  2. CSWC vs DVAX Comparison

CSWC vs DVAX Comparison

Compare CSWC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • DVAX
  • Stock Information
  • Founded
  • CSWC 1961
  • DVAX 1996
  • Country
  • CSWC United States
  • DVAX United States
  • Employees
  • CSWC N/A
  • DVAX N/A
  • Industry
  • CSWC Textiles
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSWC Consumer Discretionary
  • DVAX Health Care
  • Exchange
  • CSWC Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • CSWC 1.2B
  • DVAX 1.3B
  • IPO Year
  • CSWC N/A
  • DVAX 2004
  • Fundamental
  • Price
  • CSWC $22.90
  • DVAX $10.33
  • Analyst Decision
  • CSWC Buy
  • DVAX Buy
  • Analyst Count
  • CSWC 4
  • DVAX 4
  • Target Price
  • CSWC $24.13
  • DVAX $26.50
  • AVG Volume (30 Days)
  • CSWC 520.3K
  • DVAX 1.3M
  • Earning Date
  • CSWC 08-06-2025
  • DVAX 08-07-2025
  • Dividend Yield
  • CSWC 11.13%
  • DVAX N/A
  • EPS Growth
  • CSWC N/A
  • DVAX N/A
  • EPS
  • CSWC 1.64
  • DVAX N/A
  • Revenue
  • CSWC $209,032,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • CSWC $12.58
  • DVAX $21.18
  • Revenue Next Year
  • CSWC $12.67
  • DVAX $16.83
  • P/E Ratio
  • CSWC $13.94
  • DVAX N/A
  • Revenue Growth
  • CSWC 10.52
  • DVAX 26.66
  • 52 Week Low
  • CSWC $17.46
  • DVAX $9.22
  • 52 Week High
  • CSWC $25.90
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 56.12
  • DVAX 39.41
  • Support Level
  • CSWC $22.42
  • DVAX $10.67
  • Resistance Level
  • CSWC $23.23
  • DVAX $11.31
  • Average True Range (ATR)
  • CSWC 0.41
  • DVAX 0.45
  • MACD
  • CSWC -0.10
  • DVAX -0.08
  • Stochastic Oscillator
  • CSWC 61.84
  • DVAX 21.54

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: